Share Twitter LinkedIn Facebook Email Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L).
Targeting SCD1 in KRAS Mutant Non-Small Cell Lung Cancer: A Novel Therapeutic Strategy Non-Small Cell Lung Cancer 3 Mins Read
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read